Contact Us

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Interferons are a family of naturally occurring proteins that are produced by eukaryotic cells and mostly show action against viral infections and other biological inducers. There are three major forms of interferons that have been distinguished as alpha, beta, and gamma. The interferon beta drug represents the first class of disease modifying therapies (DMTs) for multiple sclerosis (MS) and also contributed to reseacrhers’ understanding of immunomodulatory mechanisms in MS. The drug is administered through intramuscular or subcutaneous route of administration. There are five types of interferon beta drugs; Avonex, Betaseron, Extavia, Plegridy, and Rebif in the market. The drug is available in different dosage forms such as solution, and kit (lyophilized powder in a single-dose vial for reconstitution).

The global interferon beta drugs market is estimated to be valued at US$  3,795.3 million in 2020 and is expected to exhibit a CAGR of 3.5% during the forecast period (2020-2027).

Figure 1. Global Interferon Beta Drugs Market Share (%), by Product Type, 2020

Interferon Beta Drugs  | Coherent Market Insights

Global Interferon Beta Drugs Market - Drivers

The increasing focus of market player on development of novel interferon beta drugs is another factor driving the growth of the global interferon drugs market. For instance, on July 22nd 2020, Synairgen, a company based in Southampton, UK, announced positive results from a clinical trial of SNG001 in hospitalised COVID-19 patients. SNG001 is an inhaled formulation of interferon beta. According to the study, the risk of developing severe COVID-19 symptoms during the treatment period of 16 days was reduced by 79% in the patients receiving SNG001.

Moreover, the increasing prevalence of the multiple sclerosis is expected to boost the growth of the global interferon beta drugs market. For instance, according to data published Multiple Sclerosis Trust (MST) in 2020, an estimated 2,500,000 people in the world have multiple sclerosis. Research suggests the proportion of women with MS is increasing and that around two to three women have MS. The prevalence of MS varies according to region. According to the MTS, Asia, Africa and America that lie on the equator have low prevalence of MS, while Canada and Scotland have particularly high prevalence.

request-sample

Interferon Beta Drugs Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2020: US$ 3,795.3 Mn
Historical Data for: 2016 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 3.5% 2027 Value Projection: US$ 4,825.8 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC, Israel, and Rest of the Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Product Type: Interferon Beta-1A, Interferon Beta-1B, Peginterferon Beta-1A.
  • By Route of Administration: Intramuscular, Subcutaneous, Intravenous.
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.
Companies covered:

Biogen Idec., Merck KGaA, Novartis Pharmaceuticals Corporation, and Bayer.

Growth Drivers:
  • Increasing prevalence of Multiple Sclerosis
  • Rising research and development activities
  • Increasing regulatory approval for the interferon beta drugs
Restraints & Challenges:
  • Alternative treatment for multiple sclerosis

Global Interferon Beta Drugs Market - Restraints

Interferon beta drugs are most commonly used in the treatment of multiple sclerosis. The condition can also be treated with alternative therapies such as corticosteroids, monoclonal antibodies, antineoplastic agents. Moreover, approval and launch of therapies is expected to hamper demand for interferon beta drugs. For instance, in 2017, the FDA approved Genentech’s Ocrevus (ocrelizumab) a humanized monoclonal antibody targeting B-cells with CD20 molecule. Ocrevus is the only therapy approved for both relapsing and primary progressive forms of multiple sclerosis. Thus, approval for such products is likely to hamper the growth of the global interferon beta drugs market.

Figure 2. Global Interferon Beta Drugs Market Value (US$ Mn), by Region, 2020

Interferon Beta Drugs  | Coherent Market Insights

Global Interferon Beta Drugs Market - Regional Analysis

On the basis of region, the global interferon beta drugs market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

The Europe interferon beta drugs market is expected to exhibit significant growth during the forecast period owing to presence major players, approval of interferon beta drugs, and the increasing prevalence of the MS in the region. For instance, in 2017, BIOCAD, a biotechnology company in Russia, received approval from the Russian Ministry of Health interferon beta-1a non-originator biological drug, BCD-033. The drug is a non-originator biological of Merck’s multiple sclerosis blockbuster Rebif (interferon beta-1a). Moreover, presence of major players such as Bayar, Novatis, and Merck KGaA in Europe, another factor contributing to growth of the Europe interferon beta drugs market.

Key Players:

Major players operating in the global interferon beta drugs market are Biogen Idec., Merck KGaA, Novartis Pharmaceuticals Corporation, and Bayer.

Interferon beta drug is used to treat relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. The drug does not completely cure the condition, but slows down progression of some of the disabling effects and decreases the number of relapses of the disease. Interferons are natural substances produced in the human body to help fight infections. Interferon beta drugs are categorized in Interferon Beta-1A, Interferon Beta-1B, and Peginterferon Beta-1A.

Market Dynamics

Multiple sclerosis is a widespread disabling neurological condition, mostly diagnosed in people in the age group 20–50 years. According to the Multiple Sclerosis Foundation, in 2017, this autoimmune condition affects 2.5 million people with an annual global incidence of around 7 cases per 100,000 people. The study also states that prevalence rates vary between ethnic and geographical latitudes, ranging from 50 to 120 people per 100,000. Moreover, according to the Multiple Sclerosis Foundation, 2015, an estimated 400,000 people live with the disease in U.S., and about 200 new cases are diagnosed every week. According to a survey by Healthline Media, 2015, multiple sclerosis ranks second after congestive heart failure with direct and indirect health care costs ranging from US$ 8,528 to US$ 54,244 per patient per year. Thus, increasing prevalence of multiple sclerosis is a major factor driving the growth of global interferon beta drugs market.

Key features of the study:

  • This report provides in-depth analysis of the global interferon beta drugs market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2020–2027), considering 2019 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global interferon beta drugs market based on the following parameters – company overview, financial performance, drugs portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study are Biogen Idec., Merck KGaA, Novartis Pharmaceuticals Corporation, and Bayer
  • Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future drug launches, drug class up-gradation, market expansion, and marketing tactics
  • The global interferon beta drugs market report caters to various stakeholders in this industry including investors, suppliers, drugs manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global interferon beta drugs market.

Detailed Segmentation:

  • Global Interferon Beta Drugs Market, By Product Type:
    • Interferon Beta-1A
    • Interferon Beta-1B
    • Peginterferon Beta-1A
  • Global Interferon Beta Drugs Market, By Route of Administration:
    • Intramuscular
    • Subcutaneous
    • Intravenous
  • Global Interferon Beta Drugs Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Interferon Beta Drugs Market, By Region:
    • North America
      • By Product Type:
        • Interferon Beta-1A
        • Interferon Beta-1B
        • Peginterferon Beta-1A
      • By Route of Administration:
        • Intramuscular
        • Subcutaneous
        • Intravenous
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Product Type:
        • Interferon Beta-1A
        • Interferon Beta-1B
        • Peginterferon Beta-1A
      • By Route of Administration:
        • Intramuscular
        • Subcutaneous
        • Intravenous
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Product Type:
        • Interferon Beta-1A
        • Interferon Beta-1B
        • Peginterferon Beta-1A
      • By Route of Administration:
        • Intramuscular
        • Subcutaneous
        • Intravenous
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies    
      • By Country:
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Product Type:
        • Interferon Beta-1A
        • Interferon Beta-1B
        • Peginterferon Beta-1A
      • By Route of Administration:
        • Intramuscular
        • Subcutaneous
        • Intravenous
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Product Type:
        • Interferon Beta-1A
        • Interferon Beta-1B
        • Peginterferon Beta-1A
      • By Route of Administration:
        • Intramuscular
        • Subcutaneous
        • Intravenous
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country/Region:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Product Type:
        • Interferon Beta-1A
        • Interferon Beta-1B
        • Peginterferon Beta-1A
      • By Route of Administration:
        • Intramuscular
        • Subcutaneous
        • Intravenous
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles:
    • Biogen Idec
    • Merck KGaA
    • Novartis Pharmaceuticals Corporation
    • Bayer

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Product Type
      • Market Snippet, By Route of Administration
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
      • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Impact Analysis
    • Market Opportunities
    • Collaboration and acquisition
    • Product Launch
    • Pipeline Analysis
    • Reimbursement Scenario
    • Regulatory Scenario
  4. Global Interferon Beta Drugs Market, Impact of COVID-19 Pandemic
    • Post COVID-19 Impact
    • COVID-19 Impact on Softgel Productions
    • Demand and Supply Analysis
    • Overall impact on manufacturing industry
  5. Global Interferon Beta Drugs Market, By Product Type, 2016-2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
        • Interferon Beta-1A
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
        • Interferon Beta-1B
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
        • Peginterferon Beta-1A
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
  6. Global Interferon Beta Drugs Market, By Route of Administration, 2016-2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
        • Intramuscular
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
        • Subcutaneous
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
        • Intravenous
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
  7. Global Interferon Beta Drugs Market, By Distribution Channel, 2016-2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
        • Hospital Pharmacies
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
        • Retail Pharmacies
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
        • Online Pharmacies
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
  8. Global Interferon Beta Drugs Market, By Region, 2016–2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, By Country, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, For Countries, 2017–2027
    • North America
      • Introduction
      • Market Size and Forecast, By Product Type, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Application, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016–2027 (US$ Mn)
        • U.S.
        • Canada
    • Latin America
      • Introduction
      • Market Size and Forecast, By Product Type, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Application, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016–2027 (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Introduction
      • Market Size and Forecast, By Product Type, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Application, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016–2027 (US$ Mn)
        • Germany
        • U.K.
        • France       
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Introduction
      • Market Size and Forecast, By Product Type, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Application, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016–2027 (US$ Mn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Introduction
      • Market Size and Forecast, By Product Type, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Application, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016–2027 (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Introduction
      • Market Size and Forecast, By Product Type, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Application, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016–2027 (US$ Mn)
        • South Africa
        • Central Africa
        • North Africa
  9. Competitive Landscape
    • Company Profiles
      • Biogen Idec
        • Company Overview
        • Clinical Trial Phase Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Merck KGaA
        • Company Overview
        • Clinical Trial Phase Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Novartis Pharmaceuticals Corporation
        • Company Overview
        • Clinical Trial Phase Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Bayer
        • Company Overview
        • Clinical Trial Phase Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
        • Market Strategies

 *Browse 28 market data tables and 30 figures on " Global Interferon Beta Drugs Market – Global forecast to 2027”.

Frequently Asked Questions

The global interferon beta drugs market is estimated to be valued at US$ 3,795.3 million in 2020 and is expected to exhibit a CAGR of 3.5% between 2020 and 2027.
The increasing prevalence of multiple sclerosis and research and development activities by major players are driving growth of the global interferon beta drugs market.
Interferon beta-1A is the leading segment based on product type in the global interferon beta drugs market and is estimated to hold major share in the global interferon beta drugs market during the forecast period.
Intramuscular segment is the leading segment among route of administration in the global interferon beta drugs market and is estimated to hold major share in 2020 owing to increasing focus of pharmaceutical companies on development of medicinal products in the softgels dosage form.
North America is estimated to generate the highest revenue share in 2020 in the global interferon beta drugs market during the forecast period.
Alternative treatments for multiple sclerosis are expected to hamper growth of the global interferon beta drugs market during the forecast period.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner